Biocardia Inc Total Liabilities
Biocardia Inc total liabilities. Based on the latest financial reports, Biocardia Inc (BCDA) has total liabilities worth $2.06 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Biocardia Inc liquidity resilience to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biocardia Inc (1995–2025)
Total liabilities of Biocardia Inc from 1995 to 2025. This chart illustrates how Biocardia Inc's total liabilities have evolved over time, based on quarterly financial data.
Biocardia Inc Competitors by Total Liabilities
The table below lists competitors of Biocardia Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NexturnBioscience Co. Ltd
KQ:089140
|
Korea | ₩128.65 Billion |
|
Niocan Inc
V:NIO
|
Canada | CA$216.05K |
|
Nuriplan Co. Ltd
KQ:069140
|
Korea | ₩96.67 Billion |
|
Nano Chem Tech Inc
KQ:091970
|
Korea | ₩49.56 Billion |
|
Inoviq Ltd
AU:IIQ
|
Australia | AU$2.26 Million |
|
Botanix Pharmaceuticals Ltd
AU:BOT
|
Australia | AU$47.80 Million |
|
Orbital Corporation Ltd
AU:OEC
|
Australia | AU$8.85 Million |
Liability Composition Analysis (1995–2025)
This chart breaks down Biocardia Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Biocardia Inc.
Liquidity & Leverage Metrics
Biocardia Inc Total Liabilities Ratios Explained
Biocardia Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.09 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.76 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biocardia Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biocardia Inc (1995–2025)
The table below shows the annual total liabilities of Biocardia Inc from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.52 Million | -12.78% |
| 2024-12-31 | $2.89 Million | -37.10% |
| 2023-12-31 | $4.59 Million | -6.35% |
| 2022-12-31 | $4.90 Million | -8.27% |
| 2021-12-31 | $5.34 Million | +25.78% |
| 2020-12-31 | $4.25 Million | -19.97% |
| 2019-12-31 | $5.31 Million | +102.21% |
| 2018-12-31 | $2.62 Million | +8.79% |
| 2017-12-31 | $2.41 Million | +60.87% |
| 2016-12-31 | $1.50 Million | +14900.00% |
| 2015-12-31 | $10.00K | +900.00% |
| 2014-12-31 | $1.00K | -94.44% |
| 2013-12-31 | $18.00K | +50.00% |
| 2012-12-31 | $12.00K | -98.41% |
| 2011-12-31 | $756.00K | -64.94% |
| 2010-12-31 | $2.16 Million | +153.35% |
| 2009-12-31 | $851.00K | +9.52% |
| 2008-12-31 | $777.00K | +2908.25% |
| 2007-12-31 | $25.83K | -22.59% |
| 2006-12-31 | $33.37K | -95.37% |
| 2005-12-31 | $720.54K | -2.95% |
| 2004-12-31 | $742.45K | -22.93% |
| 2003-12-31 | $963.32K | +10.92% |
| 2002-12-31 | $868.49K | +10.95% |
| 2001-12-31 | $782.74K | -32.67% |
| 2000-12-31 | $1.16 Million | +16.25% |
| 1999-12-31 | $1.00 Million | +42.86% |
| 1998-12-31 | $700.00K | +16.67% |
| 1997-12-31 | $600.00K | 0.00% |
| 1996-12-31 | $600.00K | -40.64% |
| 1995-12-31 | $1.01 Million | -- |
About Biocardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina r… Read more